论文部分内容阅读
目的方法利用液体芯片-飞行质谱技术进行血清中胶质瘤疾病相关蛋白质的筛选。结果将78例胶质瘤患者和68例正常对照者血清样本各随机分为模型建立组和模型验证组;应用液体芯片-飞行质谱技术测定模型建立组样本,进行了差异蛋白的筛选和诊断模型的建立;然后用模型验证组样本进行了差异蛋白和模型的验证;并对其中的蛋白质进行鉴定。经模型建立组胶质瘤患者与正常对照者的血清蛋白质图谱比较,得到差异蛋白17个并建立了诊断模型,建模蛋白质为1460(m/z)、1612(m/z)、1776(m/z)、1862(m/z)、1941(m/z)、3952(m/z)、4052(m/z)。模型敏感性为85%,特异性为97.06%。其中差异蛋白质1460(m/z)、1612(m/z)、2551(m/z)为肿瘤高表达,差异蛋白1941(m/z)为肿瘤低表达,经鉴定蛋白质1941(m/z)为高分子量激肽原。结论利用液体芯片-飞行质谱技术进行血清中胶质瘤疾病相关蛋白质的研究,得到了差异蛋白和诊断模型,为临床胶质瘤的诊断提供了新的思路;差异蛋白质的鉴定结果可能为胶质瘤的治疗提供有价值的途径。
Objective To screen glioma-related proteins in serum using liquid-chip mass spectrometry. Results Serum samples from 78 patients with glioma and 68 normal controls were randomly divided into model group and model validation group. Liquid microarray-flight mass spectrometry (MALDI-TOF-MS) was used to establish the model group, and the differential protein screening and diagnostic model The establishment of model validation group samples were used to verify the differential proteins and models, and the proteins were identified. A total of 17 differentially expressed proteins were obtained and their diagnostic models were established by modeling the serum protein profiles of glioma patients and normal controls. The molecular weights of the constructed proteins were 1460 (m / z), 1612 (m / z), 1776 / z), 1862 (m / z), 1941 (m / z), 3952 (m / z), 4052 (m / z). Model sensitivity was 85% and specificity was 97.06%. The differential protein 1941 (m / z) was the low expression of tumor, and the protein 1441 (m / z), 1612 (m / z) and 2551 High molecular weight kininogen. Conclusion The study of glioma disease-related proteins in serum using liquid chip-flight mass spectrometry has obtained differential proteins and diagnostic models, which provide a new idea for the diagnosis of clinical gliomas. The identification results of differential proteins may be glial The treatment of tumors provides a valuable avenue.